Objective: Observed the impact of Mangankang pill to the patients with liver stagnation and spleen deficiency syndrome in chronic hepatitis B(CHB) cellular immune function. Method: Seventy-one patients with chronic hepatitis B were enrolled and randomized into two groups:the treated group(36 cases)and the control group(35 cases).The two groups were given lamivudine treatment

the treatment group was given Mangankang pill

6 g/times

3 times/day

with a course of eight weeks. Result: The two groups can improve liver pain or discomfort

anorexia

fatigue

bloating symptoms

the treatment group better than the control group(P<0.05).No significant difference between the two groups in the improvement of alanine aminotrans ferase(ALT) and aspartate aminotrans ferase(AST).The treatment group was more significant in the reduction of hepatitis B virus(HBV)-DNA (P<0.05).Treatment group CD3+

CD4+ increased

CD8 decreased

CD4+/CD8+ increased after treatment.Differencebwas statistically significant compared with the controlngroup(P<0.05). Conclusion: Mangankang pill can improve the status of liver stagnation and spleen deficiency syndrome in patients with chronic hepatitis B-free cellular immune disorders

improve the therapeutic effect of anti-viral.